Tesamorelin

A stabilised analogue of growth-hormone-releasing hormone, approved in the US since 2010 for one specific indication.

Level of evidence

Approved as a medicine in at least one country

What it is

Tesamorelin is the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoyl group added at the N-terminus, which protects it from degradation.

State of the research

It was approved by the FDA in 2010 to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, on the basis of randomised clinical trials. Its effects and side effects are documented in the official product information.

Sources

PubMed — tesamorelin
U.S. FDA — Drugs@FDA (approved medicines)
WADA — Prohibited List

Last reviewed: October 2026

Summaries of published scientific literature, for information and laboratory research only. They do not describe uses of our products, are not medical advice and do not imply that any compound is safe or effective in humans. Our products are not for human or animal consumption.